Tipifarnib, Cytarabine, and Daunorubicin in Treating Older Patients With Acute Myeloid Leukemia
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
RATIONALE: Tipifarnib may stop the growth of cancer cells by blocking some of the enzymes
needed for cell growth. Drugs used in chemotherapy, such as cytarabine and daunorubicin, work
in different ways to stop the growth of cancer cells, either by killing the cells or by
stopping them from dividing. Giving tipifarnib together with cytarabine and daunorubicin may
kill more cancer cells.
PURPOSE: This phase I trial is studying the side effects and best dose of tipifarnib when
given with cytarabine and daunorubicin in treating older patients with acute myeloid
leukemia.